ArticleInternational journal of hematology2026
Anticoagulant protein activity value thresholds for the occurrence of venous thromboembolism in pregnant women with thrombophilia.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study estimated anticoagulant protein activity value thresholds for the occurrence of venous thromboembolism (VTE) in pregnant women with thrombophilia using national surveillance data. Activity values at diagnosis of thrombophilia were obtained in 77 patients with antithrombin (AT) deficiency, 40 with protein C (PC) deficiency, and 237 with protein S (PS) deficiency. Patients were classified into 11 groups by the occurrence of VTE associated with the current pregnancy, and by family and/or past history of VTE. The median activity values in all patients were 45.8% for AT, 51.0% for PC, and 41.0% for PS. Neither AT nor PC activity differed significantly across the evaluated groups. However, PS activity was lower in the group of all patients with VTE than in the group with no VTE and no family or past history of VTE (34.9 ± 11.8% vs. 44.5 ± 12.6%), indicating an association between lower PS activity and VTE occurrence. ROC-based optimization identified PS ≤ 43% as the most discriminative cutoff value, with a higher estimated risk ratio of 4.02. In contrast, a clinically plausible threshold of PS ≤ 35% yielded a risk ratio of 3.34. Our data may be helpful in determining whether to provide peripartum thromboprophylaxis in pregnant women with thrombophilia.
Indexed as
Identifiers
42828643What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.